Put the money toward research, treatment and finding ways to better the health of everyone, the same as we did with tobacco settlements.

All of the choices now available to Medicare recipients could live on, even in a single-payer system.

The U.S. government and pharmaceutical companies can’t seem to solve the problem, but some creative work-arounds are taking shape.

Its a multibillion-dollar industry, but do all those products do what they claim? Consumers have no way of knowing.

When you get your medicine by mail order, you lose the chance to have a convenient consultation about what you’re taking.

New federal rules require medical facilities to post spreadsheets itemizing their charges. Computers can read them, but people can’t.

Medical aid in dying is only an option for those with six months or less to live, but even still-healthy people may want to know how the new law could apply to them.

The U.S. takes forever to approve drugs before they can be sold to the public, but no such caution is taken with new devices.

Big companies are self-insuring themselves and taking other steps to control medical costs. Is this a return to plantation days?

Hospitals and patients would save money if the two options were offered in one venue, because many people go to ERs for nonemergencies.

Cost controls on the pharmaceutical industry are sorely needed as testing and treatment advance.

It’s time for the federal program to eliminate a rule that prevents timely transfers of patients from hospitals to skilled nursing facilities.